Expression of immunomodulating molecules by recombinant viruses: can the immunogenicity of live virus vaccines be improved?

References

• Collins PL, Whitehead SS, Bukreyev A et al Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv Virus Res. 54,423–451 (1999).
   PubMed Web of Science ®Google Scholar
• Siegrist C, Saddallah F, Tougne C, Martinez X, Kovarik J, Lambert PH. Induction of neonatal TH1 and CTL responses by live viral vaccines: a role for replication patterns within antigen-presenting cells? Vaccine 16, 1473–1478 (1998).
   PubMed Web of Science ®Google Scholar
• Barrios C, Brawand P, Berney M, Brandt C, Lambert PH, Siegrist CA. Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting. Eur. Immunol 26,1489–1496 (1996).
   Google Scholar
• Swain SL, Weinberg AD, English M, Huston G. IL-4 directs the development of Th2-like helper effectors. J. Immunol 145, 3796–3806 (1990).
   Google Scholar
• Seko Y, Takahashi N, Yagita H, Okumura K, Yazaki Y. Expression of cytokine mRNAs in murine hearts with acute myocarditis caused by coxsackievirus b3. j Path& 183, 105–108 (1997).
   Google Scholar
• Kramer JM, LaRussa P, Tsai WC et al. Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics 108, E39 (2001).
   Google Scholar
• Berzofsky JA, Ahlers JD, Derby MA, Pendleton CD, Arichi T, Belyakov IM. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. Immunol Rev 170,151–172 (1999).
   PubMed Web of Science ®Google Scholar
• Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat. Rev Immunol 1, 209–219 (2001).
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Hel Z, Kelsall B et al. Mucosa' AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat. Med. 7,1320–1326 (2001).
   PubMed Web of Science ®Google Scholar
• Flexner C, Hugin A, Moss B. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature 330,259–262 (1987).
   Google Scholar
• Ramshaw IA, Andrew ME, Phillips SM, Boyle DB, Coupar BE. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 329,545–546 (1987).
   Google Scholar
• Flexner C, Moss B, London WT, Murphy BR. Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2. Vaccine 8, 17–21 (1990).
   PubMed Web of Science ®Google Scholar
• Kohonen-Corish MR, King NJ, Woodhams CE, Ramshaw IA. Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma. Eur. j Immunol 20, 157–161 (1990).
   Google Scholar
• Karupiah G, Woodhams CE, Blanden RV, Ramshaw IA. Immunobiology of infection with recombinant vaccinia virus encoding murine IL-2. Mechanisms of rapid viral clearance in immunocompetent mice. j Immunol 147,4327–4332 (1991).
   Google Scholar
• Bukreyev A, Whitehead SS, Prussin C, Murphy BR, Collins PL. Effect of coexpression of interleukin-2 by recombinant respiratory syncytial virus on virus replication, immunogenicity and production of other cy tokines.J. Virol 74, 7151–7157 (2000).
   Google Scholar
• Guncllach BR, Linhart H, Dittrner U et al. Construction, replication and immunogenic properties of a simian immunodeficiency virus expressing interleukin-2. j Virol 71, 2225–2232 (1997).
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Whitehead SS, Bukreyeva N, Murphy BR, Collins PL. Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity. Proc. Natl Acad. Sci. USA 96,2367–2372 (1999).
   Google Scholar
• Johnson TR, Fischer JE, Graham BS. Construction and characterization of recombinant vaccinia viruses co-expressing a respiratory syncytial virus protein and a cytokine.j Gen. Virol 82,2107–2116 (2001).
   Google Scholar
• Giavedoni LD, Yilma T. Construction and characterization of replication-competent simian immunodeficiency virus vectors that express gamma interferon. J. Virol 70, 2247–2251 (1996).
   PubMed Web of Science ®Google Scholar
• Giavedoni L, Ahmad S, Jones L, Yilma T. Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques. J. Virol 71,866–872 (1997).
   PubMed Web of Science ®Google Scholar
• Giavedoni LD, Imhoof JD, Velasquillo MC, Parodi LM, Hodara VL. Expression of the interleukin-18 gene from rhesus macaque by the simian immunodeficiency virus does not result in increased viral replication. J. Interferon Cytokine Res. 21, 173–180 (2001).
   Google Scholar
• Karaca K, Sharma JM, Winslow BJ et al. Recombinant fowlpox viruses coexpressing chicken Type I IFN and Newcastle disease virus HN and F genes: influence of IFN on protective efficacy and humoral responses of chickens following in ovo or post- hatch administration of recombinant viruses. Vaccine 16,1496–1503 (1998).
   PubMed Web of Science ®Google Scholar
• Rautenschlein S, Sharma JM, Winslow BJ, McMillen J, Junker D, Cochran M. Embryo vaccination of turkeys against Newcastle disease infection with recombinant fowlpox virus constructs containing interferons as adjuvants. Vaccine 18,426–433 (1999).
   PubMed Web of Science ®Google Scholar
• Leong KH, Ramshaw IA, Ramsay AJ. Interleukin-7 enhances cell-mediated immune responses in vivo in an interleukin-2-dependent manner. Viral Immunol 10, 1–9 (1997).
   Google Scholar
• Kurilla MG, Swaminathan S, Welsh RM, Kieff E, Brutkiewicz RR. Effects of virally expressed interleukin-10 on vaccinia virus infection in mice. J. Virol 67,7623–7628 (1993).
   Google Scholar
• Bukreyev A, Belyakov IM, Berzofsky JA, Murphy BR, Collins PL. Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. J. Virol 75, 12128–12140 (2001).
   Google Scholar
• Tamashiro VG, Perez HH, Griffin DE. Prospective study of the magnitude and duration of changes in tuberculin reactivity during uncomplicated and complicated measles. Pediatr. Infect. Dis. j 6,451–454 (1987).
   Google Scholar
• Hussey GD, Goddard EA, Hughes J et al. The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune response in infants. J. Infect. Dis. 173, 1320–1326 (1996).
   PubMed Web of Science ®Google Scholar
• Singh M, Billeter MA. A recombinant measles virus expressing biologically active human interleukin-12. J. Gen. Virol. 80, 101–106 (1999).
   Google Scholar
• Ramsay AJ, Husband AJ, Ramshaw IA et al. The role of interleukin-6 in mucosa' IgA antibody responses in vivo. Science 264, 561–563 (1994).
   PubMed Web of Science ®Google Scholar
• Ramsay AJ, Leong KH, Boyle D, Ruby J, Ramshaw IA. Enhancement of mucosa' IgA responses by interleukins 5 and 6 encoded in recombinant vaccine vectors. Reprod. Feral. Dev. 6,389-392 (1994).
   Google Scholar
• Leong KH, Ramsay AJ, Boyle DB, Ramshaw IA. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. j Virol. 68, 8125–8130 (1994).
   PubMed Web of Science ®Google Scholar
• Tian J, Olcott AP, Hanssen LR, Zekzer D, Middleton B, Kaufman DL. Infectious Thl and Th2 autoimmunity in diabetes-prone mice. Immunol. Rev 164,119–127 (1998).
   Google Scholar
• Cameron MJ, Arreaza GA, Zucker P et al. IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J. Immunol. 159, 4686–4692 (1997).
   Google Scholar
• Chapman NM, Kim KS, Tracy S et al. Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice. j Virol. 74,7952–7962 (2000).
   PubMed Web of Science ®Google Scholar
• Manickan E, Francotte M, Kuklin N et al. Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Thl+ T cells. j Virol. 69, 4711–4716 (1995).
   PubMed Web of Science ®Google Scholar
• Kuklin NA, Daheshia M, Marconi PC et al. Modulation of mucosa' and systemic immunity by enteric administration of nonreplicating herpes simplex virus expressing cytokines. Virology240,245–253 (1998).
   PubMed Web of Science ®Google Scholar
• Sharma DP, Ramsay AJ, Maguire DJ, Rolph MS, Ramshaw IA. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxicT-lymphocyte responses and exacerbates vaccinia virus infection in vivo. j Virol. 70, 7103–7107 (1996).
   Google Scholar
• Jackson RJ, Ramsay AJ, Christensen CD, Beaton S, Hall DF, Ramshaw IA. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. Virol. 75,1205–1210 (2001).
   Web of Science ®Google Scholar
• Valmori D, Levy F, Miconnet I et al. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. Immunol. 164,1125–1131 (2000).
   Web of Science ®Google Scholar
• Hodge JVV, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15,759–768 (1997).
   PubMed Web of Science ®Google Scholar
• Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JVV. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res. 59,676–683 (1999).
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Flanagan K, Lee CS, Perretta DJ, Hong H. Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine 20,1862–1869 (2002).
   Google Scholar
• Yamazaki M, Zhang R, Straus FH et al. Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12. Gene Ther. 9, 64–74 (2002).
   PubMed Web of Science ®Google Scholar
• Elzey BD, Siemens DR, Ratliff TL, Lubaroff DM. Immunization with Type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int. Cancer94, 842–849 (2001).
   Google Scholar
• Schlom J, Hodge JVV. The diversity of T- cell co-stimulation in the induction of antitumor immunity. Immunol. Rev 170, 73–84 (1999).
   PubMed Web of Science ®Google Scholar
• Kalus RM, Kantor JA, Gritz L et al. The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation. Vaccine 17,893–903 (1999).
   PubMed Web of Science ®Google Scholar
• Akagi J, Hodge JVV, McLaughlin JP et al. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUCI gene and the murine T-cell costimulatory molecule B7.1. Immunother. 20,38-47 (1997).
   Google Scholar
• Chamberlain RS, Carroll MW, Bronte V et al. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res. 56,2832–2836 (1996).
   PubMed Web of Science ®Google Scholar
• Carroll MW, Overwijk WW, Surman DR, Tsung K, Moss B, Restifo NP. Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12 and a model tumor antigen. j Natl Cancer Inst. 90,1881–1887 (1998).
   PubMedGoogle Scholar
• Liu Y, Zhang X, Zhang W eta]. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity. Cancer Gene Ther. 9, 202–208 (2002).
   Google Scholar
• Kikuchi T, Moore MA, Crystal RG. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 96,91–99 (2000).
   Google Scholar
• Kikuchi T, Worgall S, Singh R, Moore MA, Crystal RG. Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4+ T cells. Nat. Med. 6,1154-1159 (2000).
   Google Scholar
• Bukreyev A, Camargo E, Collins PL. Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene. Virol. 70,6634–6641 (1996).
   Google Scholar
• Ahlers JD, Belyakov IM, Matsui S, Berzofsky JA. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int. Immunol. 13, 897–908 (2001).
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Moss B, Strober W, Berzofsky JA. Mucosa' vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl Acad. Sci. USA 96,4512–4517 (1999).
   PubMed Web of Science ®Google Scholar
• Ramirez JC, Gherardi MM, Rodriguez D, Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. j Virol. 74,7651–7655 (2000).
   PubMed Web of Science ®Google Scholar
• Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol. 17,253–258 (1999).
   PubMed Web of Science ®Google Scholar
• Biragyn A, Surenhu M, Yang D et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. j Immunol. 167,6644–6653 (2001).
   PubMed Web of Science ®Google Scholar
• Biragyn A, Belyakov IM, Chow YH, Dimitrov DS, Berzofsky JA, Kwak LW DNA vaccines encoding HIV-1 gp120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood In press (2002).
   Google Scholar
• Cheers C, Janas M, Ramsay A, Ramshaw I. Use of recombinant viruses to deliver cytokines influencing the course of experimental bacterial infection. Immunol. Cell Biol. 77,324–330 (1999).
   PubMed Web of Science ®Google Scholar
• Rao JB, Chamberlain RS, Bronte V et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. Immuna 156,3357–3365 (1996).
   PubMed Web of Science ®Google Scholar
• Hodge JVV, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59, 5800–5807 (1999).
   PubMed Web of Science ®Google Scholar
• Zhu M, Terasawa H, Gulley J et al. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res. 61, 3725–3734 (2001).
   PubMed Web of Science ®Google Scholar
• Aung S, Tang YW, Graham BS. Interleukin-4 diminishes CD8(+) respiratory syncytial virus-specific cytotoxic T-lymphocyte activity in vivo. j Virol. 73, 8944–8949 (1999).
   Google Scholar
• Perera LP, Goldman CK, Waldmann TA. Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice. Proc. Natl Acad. Sci. USA 98,5146–5151 (2001).
   Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4,321–327 (1998).
   PubMed Web of Science ®Google Scholar
• Barouch DH, Santra S, Schmitz JE et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290,486–492 (2000).
   PubMed Web of Science ®Google Scholar
• McLaughlin JP, Schlom J, Kantor JA, Greiner JVV. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res. 56,2361–2367 (1996).
   PubMed Web of Science ®Google Scholar
• Kim JJ, Yang JS, Manson KH, Weiner DB. Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants. Vaccine 19,2496–2505 (2001).
   PubMed Web of Science ®Google Scholar
• Kim JJ, Yang JS, Montaner L, Lee DJ, Chalian AA, Weiner DB. Coimmunization with IFN-gamma or IL-2, but not IL-13 or IL-4 cDNA can enhance Thl-type DNA vaccine-induced immune responses in vivo. Interferon Cytokine Res. 20,311–319 (2000).
   PubMed Web of Science ®Google Scholar
• Mack DG, Jaffe HA. Effect of administration of a recombinant adenovirus expressing the genes for IFN-gamma and interleukin-12 on acute murine toxoplasmosis. J. Interferon Cytokine Res. 21,777-783 (2001).
   Google Scholar
• Tuttle TM, McCrady CW, Inge TH, Salour M, Bear HD. gamma-Interferon plays a key role in T-cell-induced tumor regression. Cancer Res. 53,833–839 (1993).
   Google Scholar
• Hara I, Taguchi I, Miyake H, Hara S, Gotoh A, Kamidono S. Effects of retinoic acid and interferon-gamma on expression of the retinoic acid receptor in mouse renal cell carcinoma. Int.j Oncol. 19,959–962 (2001).
   PubMed Web of Science ®Google Scholar
• Xiang Z, Ertl HC. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2, 129–135 (1995).
   PubMed Web of Science ®Google Scholar
• Yamano S, Scott DE, Huang LY et al. Protection from experimental endotoxemia by a recombinant adeno- associated virus encoding interleukin 10. j Gene Med. 3, 450–457 (2001).
   PubMed Web of Science ®Google Scholar
• Nakase H, Okazaki K, Tabata Y et al. New cytokine delivery system using gelatin microspheres containing interleukin-10 for experimental inflammatory bowel disease. Pharmacol. Exp. Ther. 301,59-65 (2002).
   Google Scholar
• Kaufman HL, Rao JB, Irvine KR et al. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. j Immunother. 22,489–496 (1999).
   PubMed Web of Science ®Google Scholar
• Lee CT, Wu S, Ciernik IF et al. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum. Gene Ther. 8,187–193 (1997).
   PubMed Web of Science ®Google Scholar
• Ahlers JD, Dunlop N, Ailing DVV, Nara PL, Berzofsky JA. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. j Immunol 158, 3947–3958 (1997).
   Google Scholar
• Kim JJ, Trivedi NN, Nottingham LK et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur. Immunol. 28,1089–1103 (1998).
   PubMed Web of Science ®Google Scholar
• Colmenero P, Chen M, Castanos-Velez E, Liljestrom P, Jondal M. Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. bit. j Cancer 98,554–560 (2002).
   Google Scholar
• Gonzalo RM, Rodriguez JR, Rodriguez D, Gonzalez-Aseguinolaza G, Larraga V, Esteban M. Protective immune response against cutaneous leishmaniasis by prime/ booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36. Microbes Infect. 3,701-711(2001).
   Google Scholar
• Mazzolini G, Narvaiza I, Perez-Diez A et al. Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12. Gene The,: 8,259–26 (2001).
   Web of Science ®Google Scholar
• Belyakov IM, Ahlers JD, Brandwein BY et al. The importance of local mucosa' HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. Clin. Invest. 102,2072-2081 (1998).
   Google Scholar
• Belyakov IM, Ahlers JD, Clements JD, Strober W, Berzofsky JA. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL. Immunol. 165,6454–6462 (2000).
   Google Scholar
• Ansari AA, Mayne AE, Sundstrom JB et al. Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SW) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques. j Virol. 76,1731–1743 (2002).
   PubMed Web of Science ®Google Scholar
• Ahlers JD, Belyakov IM, Matsui S, Berzofsky JA. Signals delivered through TCR instruct IL-12 receptor (IL-12R) expression: IL-12 and tumor necrosis factor-alpha synergize for IL-12R expression at low antigen dose. InL Immunol. 13, 1433–1442 (2001).
   PubMed Web of Science ®Google Scholar
• Glansbeek HL, Haagmans BL, te Lintelo EG et al Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus. J. Gen. Virol. 83, 1–10 (2002).
   Google Scholar
• Lui VW, Falo LD, Jr., Huang L. Systemic production of IL-12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expression in vivo. J. Gene Med. 3, 384–393 (2001).
   Google Scholar
• Boyer JD, Cohen AD, Ugen KE et al. Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids. Alps 14, 1515–1522 (2000).
   Google Scholar
• Sin JI, Kim JJ, Arnold RL et al. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Thl-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. J. Immunol. 162, 2912–2921 (1999).
   Google Scholar
• Chapoval Al, Fuller JA, Kremlev SG, Kamdar SJ, Evans R. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J. Immunol. 161, 6977–6984 (1998).
   Google Scholar
• Cao S, Troutt AB, Rustum YM. Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. Cancer Res. 58, 1695–1699 (1998).
   Google Scholar
• Evans R, Fuller JA, Christianson G, Krupke DM, Troutt AB. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations. Cell Immunol. 179, 66–73 (1997).
   Google Scholar
• Meazza R, Lollini PL, Nanni P et al. Gene transfer of a secreTable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response. Int. J. Cancer. 87, 574–581 (2000).
   Google Scholar
• Xin KQ, Hamajima K, Sasaki S et al. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine 17, 858–866 (1999).
   PubMed Web of Science ®Google Scholar